Exagen (XGN) Cash & Equivalents (2018 - 2026)

Exagen has reported Cash & Equivalents for 9 years, with the latest figure at $21.5 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 92.18% year-over-year to $21.5 million; the trailing twelve-month figure through Mar 2026 stood at $21.5 million (up 92.18% YoY), and the FY2025 full-year result was $32.2 million, up 46.22% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $21.5 million, down from $32.2 million in the prior quarter.
• The five-year high for Cash & Equivalents was $89.8 million in Q1 2022, with the low at $11.2 million in Q1 2025.
• Historically, Cash & Equivalents has averaged $39.5 million across 5 years, with a median of $31.5 million in 2023.
• Annual changes were most pronounced in 2025 — Cash & Equivalents sank 59.0% — and 2026, when it jumped 92.18%.
• Exagen's Cash & Equivalents stood at $62.4 million in 2022, then tumbled by 41.51% to $36.5 million in 2023, then tumbled by 39.62% to $22.0 million in 2024, then soared by 46.22% to $32.2 million in 2025, then plunged by 33.23% to $21.5 million in 2026.
• The last three Cash & Equivalents figures came in at $21.5 million (Q1 2026), $32.2 million (Q4 2025), and $35.7 million (Q3 2025), per Business Quant data.